Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last1,941 to 1,960 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| VAX-MOM COVID-19 Intervention vs Standard of Care: Rate of COVID-19 Vaccination (6 Month) | 251 of 2,789 130 of 1,759 | 1.6 points -0.0 to 3.2 | 4,548 | NCT05570630 VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination |
| Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership vs Control: Number of Participants With a NICU Admission of at Least Overnight | 241 of 3,046 128 of 1,497 | -0.6 points -2.4 to 1.0 | 4,543 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| 3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Iron Therapy | 116 of 2,265 122 of 2,269 | -0.3 points -1.6 to 1.0 | 4,534 | NCT03252249 Duration of Dual Anti-Platelet Therapy (DUAL-ACS) |
| Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants Who Received a Gestational Diabetes Test (24-28 Weeks) | 1,747 of 3,028 869 of 1,502 | -0.2 points -3.2 to 2.9 | 4,530 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| Drug-specific Alert vs Usual Care: Percentage of Patients With AKI Progression From Stage 1 to Stage 2 | 242 of 2,279 248 of 2,248 | -0.4 points -2.2 to 1.4 | 4,527 | NCT02771977 Drug-Targeted Alerts for Acute Kidney Injury |
| QIVc (≥2 Years to <18 Years of Age) vs Non-Influenza Comparator Vaccine: deaths from any cause | 0 of 2,258 1 of 2,255 | -0.0 points -0.3 to 0.1 | 4,513 | NCT03165617 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age |
| QIVc (≥2 Years to <18 Years of Age) vs Non-Influenza Comparator Vaccine: serious adverse events | 25 of 2,258 30 of 2,255 | -0.2 points -0.9 to 0.4 | 4,513 | NCT03165617 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age |
| RotaTeq™ vs Placebo: Occurrence of Rotavirus Disease Caused by Serotypes G1, G2, G3 and G4 That Occurs 14 Days Following the 3rd Vaccination | 82 of 2,207 315 of 2,305 | -10.0 points -11.6 to -8.3 | 4,512 | NCT00090233 Rotavirus Efficacy and Safety Trial (REST)(V260-006) |
| Pregnant Women/Mothers Group vs Neonates/Infants Group: deaths from any cause | 1 of 2,311 23 of 2,181 | -1.0 points -1.5 to -0.6 | 4,492 | NCT03614676 A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance |
| Randomization Period: Exemestane vs Randomization Period: Placebo: Incidence of All Clinical Fractures | 149 of 2,240 143 of 2,248 | 0.3 points -1.2 to 1.7 | 4,488 | NCT00083174 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| Randomization Period: Exemestane vs Randomization Period: Placebo: Incidences of Other Malignancies | 50 of 2,240 42 of 2,248 | 0.4 points -0.5 to 1.2 | 4,488 | NCT00083174 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| Randomization Period: Exemestane vs Randomization Period: Placebo: Incidence of Clinically Relevant Cardiac Events | 106 of 2,240 111 of 2,248 | -0.2 points -1.5 to 1.1 | 4,488 | NCT00083174 Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer |
| IDTFK Group Pre-NIPT (January 2010-July 2010) vs IDTFK Group Post NIPT - (January 2012-June 2014): Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market | 1,414 of 1,414 3,074 of 3,074 | 0.0 points -0.3 to 0.1 | 4,488 | NCT02284399 National Prevalence and Impact of Noninvasive Prenatal Testing |
| IDTFK Group Post NIPT - (January 2012-June 2014) vs IDTFK Group Pre-NIPT (January 2010-July 2010): Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing. | 454 of 3,074 104 of 1,414 | 7.4 points 5.5 to 9.2 | 4,488 | NCT02284399 National Prevalence and Impact of Noninvasive Prenatal Testing |
| Colchicine vs Placebo: Number of Participants Who Required Mechanical Ventilation in the 30 Days Following Randomization. | 11 of 2,235 21 of 2,253 | -0.4 points -1.0 to 0.1 | 4,488 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Colchicine vs Placebo: Number of Deaths in the 30 Days Following Randomization. | 5 of 2,235 9 of 2,253 | -0.2 points -0.6 to 0.2 | 4,488 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Colchicine vs Placebo: Number of Participants Who Died or Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization. | 104 of 2,235 131 of 2,253 | -1.2 points -2.5 to 0.1 | 4,488 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Colchicine vs Placebo: Number of Participants Who Were Hospitalized Due to COVID-19 Infection in the 30 Days Following Randomization. | 101 of 2,235 128 of 2,253 | -1.2 points -2.5 to 0.1 | 4,488 | NCT04322682 Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA) |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | 20 of 2,238 81 of 2,246 | -2.7 points -3.6 to -1.9 | 4,484 | NCT00141102 Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms | 132 of 2,238 162 of 2,246 | -1.3 points -2.8 to 0.1 | 4,484 | NCT00141102 Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis |
Code
curl "https://conductscience.org/api/comparisons/v1?page=98"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=98
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT05570630-704e061d",
"title": "VAX-MOM COVID-19 Intervention vs Standard of Care: Rate of COVID-19 Vaccination (6 Month)",
"summary": "251 of 2789 against 130 of 1759; risk difference 1.6 points, 95% interval -0.0 to 3.2; NCT05570630, VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination",
"record": "/library/comparisons/NCT05570630-704e061d",
"nct_id": "NCT05570630",
"kind": "outcome",
"participants": 4548,
"risk_difference": {
"value": 0.016090786287638992,
"lower": -0.0004896596988651185,
"upper": 0.03200925260482681
},
"group_1": "251 of 2,789",
"group_2": "130 of 1,759",
"difference": "1.6 points",
"interval": "-0.0 to 3.2",
"trial_title": "VAX-MOM COVID-19: Increasing Maternal COVID-19 Vaccination"
},
{
"id": "NCT03360539-3d4873ae",
"title": "Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership vs Control: Number of Participants With a NICU Admission of at Least Overnight",
"summary": "241 of 3046 against 128 of 1497; risk difference -0.6 points, 95% interval -2.4 to 1.0; NCT03360539, Nurse-Family Partnership Impact Evaluation in South Carolina",
"record": "/library/comparisons/NCT03360539-3d4873ae",
"nct_id": "NCT03360539",
"kind": "outcome",
"participants": 4543,
"risk_difference": {
"value": -0.006384184433651727,
"lower": -0.02412264999152204,
"upper": 0.010192731630365222
},
"group_1": "241 of 3,046",
"group_2": "128 of 1,497",
"difference": "-0.6 points",
"interval": "-2.4 to 1.0",
"trial_title": "Nurse-Family Partnership Impact Evaluation in South Carolina"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=99",
"request_id": "IsljZsTIfrorIMLp"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant